about
Functions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic DisordersFGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological featuresHyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma.Genetics of endometrial cancersERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancerCurrent status in the management of uterine corpus cancer in KoreaIntegrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.The role of lymphadenectomy in surgical staging of endometrial cancer.L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial CarcinomaAntitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.Biomarkers in endometrial cancer: Possible clinical applications (Review)Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform.Research resource: the Endometrium Database Resource (EDR).Evaluation of expression of the PTEN gene, oestrogen and progesterone receptors as diagnostic and predictive factors in endometrial cancer.Clinicopathologic study in uterine cancer.Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?What is the role of chemotherapy in endometrial cancer?The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer.Obesity-related proliferative diseases: the interaction between adipose tissue and estrogens in post-menopausal women.Proteomics of endometrial cancer diagnosis, treatment, and prognosis.Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models.Overexpression of Fli-1 is associated with adverse prognosis of endometrial cancer.Clinical implications of estrone sulfate measurement in laboratory medicine.Efficacy of para-aortic lymphadenectomy in early-stage endometrioid uterine corpus cancer.Discovery of biomarkers for endometrial cancer: current status and prospects.The comparison of clinicopathological characteristics in primary malignant mixed műllerian tumour with epithelial endometrial carcinoma.
P2860
Q28082264-F08DA96D-6A32-4AE8-A2BE-0AA5506E901FQ28731816-5CB706F5-5D95-4E27-BD1C-93C22FF14C67Q33704516-87BEFFBB-1D9C-4C47-BE53-5C7ED288B3BDQ33781274-9D86B30C-FA23-49CB-B4E1-40DE311E25F9Q33911196-ABC600E0-8FEB-4A6F-BB06-C2D3DB242065Q34016911-AA2960F7-774B-4836-BDA3-F579C8DC8B67Q34167041-A8EE26FF-B4FD-4D22-87B0-8796565D4A75Q34580883-FBB04F43-34B0-4F89-9C31-241006A79A44Q34727321-E06B1AE4-C0D9-4B65-937E-F0A2A2208659Q35687573-FB289762-6D1C-42F6-9AD5-AFAB1359D4D1Q35927619-8E464FFC-20D2-442E-9EBC-6E9214A4B2E5Q35972278-ED06789D-C430-4C44-B78D-53229CDFC13DQ36084326-263350EF-8E15-4193-945C-7A4FC9DBEF8BQ36356015-AF324509-AD9A-4E92-9202-C8A9E928D8F6Q36660596-888C7E65-BBAC-4907-AF91-A806E71CDADCQ37471173-DBACE428-0508-4A5F-9585-2F8FE84A0973Q37709899-E1330D1D-6C8F-4B80-A89C-8D0995EE8A53Q37854068-D1FA3F3D-1A1B-4674-AB91-A016698B78AAQ37923341-34B3017B-DB57-4F77-983B-78A8547AB350Q38250639-5BE0D731-F8BC-46C4-9382-5A1D798C648FQ38381450-75BFF0E7-3FE1-4733-916B-426CFFEE1867Q38626386-5384B66F-7B26-4533-BE07-E80D6DC17E18Q38737146-77FEC01A-0DB6-47FC-A4C0-8E3FCB3CC36DQ38840961-14520300-DDBA-4E59-92FA-0BEB77C05A14Q39037694-5B74FC65-9EB8-44F3-BFB1-B933E6AA29A0Q44100659-35DAC1EF-BFB9-4517-89E2-C4F55D77ACDEQ51341963-3F932A3A-6999-4429-82A2-2449C91CD68AQ53393943-66606416-8B8B-445E-BD5F-46113CEB5733
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biologic markers in endometrial cancer treatment.
@en
Biologic markers in endometrial cancer treatment.
@nl
type
label
Biologic markers in endometrial cancer treatment.
@en
Biologic markers in endometrial cancer treatment.
@nl
prefLabel
Biologic markers in endometrial cancer treatment.
@en
Biologic markers in endometrial cancer treatment.
@nl
P1476
Biologic markers in endometrial cancer treatment.
@en
P2093
Helga B Salvesen
Ingeborg B Engelsen
P304
P356
10.1111/J.1600-0463.2009.02467.X
P577
2009-10-01T00:00:00Z